uncomplicated urinary tract infections

Sep 28, 2026

Summary After years of a stalled pipeline, 2026 brought two major FDA antibiotic approvals, GSK/Spero Therapeutics’ UTEBZI (tebipenem pivoxil) and Wockhardt’s ZAYNICH (cefepime and zidebactam), signaling real progress against drug-resistant infections. Resistant bacteria are turning routine infections into m...

Nov 08, 2024

Urinary tract infections (UTIs) are among the most prevalent bacterial infections in the US and globally. Around 60% of women will experience an uncomplicated UTI (uUTI) during their lifetime, and up to 40% of women with a history of uUTIs may face a recurrence, according to Iterum’s approval announcement. In 20...